This Article  • Full text  • PDF  • CME Course for This Article  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Cerebrovascular Disease  • Neurology, Other  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

The Rotterdam Scan Study

Meike W. Vernooij, MD; Mendel D. M. Haag, PharmD; Aad van der Lugt, MD, PhD; Albert Hofman, MD, PhD; Gabriel P. Krestin, MD, PhD; Bruno H. Stricker, MB, PhD; Monique M. B. Breteler, MD, PhD

Arch Neurol. 2009;66(6):714-720. Published online April 13, 2009 (doi:10.1001/archneurol.2009.42).

Background  Cerebral microbleeds are hemosiderin deposits in the brain that are indicative of microangiopathy. Microbleeds in strictly lobar brain locations have been related to cerebral amyloid angiopathy, a bleeding-prone disease state.

Objective  To investigate the relation between antithrombotic drug use and the presence of cerebral microbleeds, especially those in strictly lobar locations.

Design  A population-based, cross-sectional analysis that used magnetic resonance imaging (MRI) to assess the presence and location of microbleeds. Complete information on outpatient use of platelet aggregation inhibitors and anticoagulant drugs before MRI was obtained from automated pharmacy records.

Setting  The Rotterdam Scan Study, a population-based imaging study in a general elderly community in the Netherlands.

Participants  A population-based sample of 1062 persons from a longitudinal cohort, 60 years and older, free of dementia, who underwent MRI examinations between August 15, 2005, and November 22, 2006.

Main Outcome Measures  Presence of cerebral microbleeds on MRI.

Results  Compared with nonusers of antithrombotic drugs, cerebral microbleeds were more prevalent among users of platelet aggregation inhibitors (adjusted odds ratio [OR], 1.71; 95% confidence interval [CI], 1.21-2.41). We did not find a significant association for anticoagulant drugs and microbleed presence (OR, 1.49; 95% CI, 0.82-2.71). Strictly lobar microbleeds were more prevalent among aspirin users (adjusted OR compared with nonusers, 2.70; 95% CI, 1.45-5.04) than among persons using carbasalate calcium (adjusted OR, 1.16; 95% CI, 0.66-2.02). This difference was even more pronounced when comparing persons who had used similar dosages of both drugs.

Conclusions  This cross-sectional study shows that use of platelet aggregation inhibitors is related to the presence of cerebral microbleeds. Furthermore, aspirin and carbasalate calcium use may differently relate to the presence of strictly lobar microbleeds.

Author Affiliations: Departments of Epidemiology (Drs Vernooij, Haag, Hofman, Stricker, and Breteler) and Radiology (Drs Vernooij, van der Lugt, and Krestin), Erasmus MC University Medical Center, Rotterdam, the Netherlands.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

This Month in Archives of Neurology
Arch Neurol. 2009;66(6):689-690.
FULL TEXT  

Cerebral Microbleeds: Evidence of Heightened Risk Associated With Aspirin Use
Philip B. Gorelick
Arch Neurol. 2009;66(6):691-693.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cerebral Microbleeds: Evidence of Heightened Risk Associated With Aspirin Use
Gorelick
Arch Neurol 2009;66:691-693.
FULL TEXT